Latest News and Press Releases

BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

- Brings extensive business development and licensing experience to resTORbio’s Board - BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical...

RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition to decreasing the incidence of...

BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

BOSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical biopharmaceutical company focused on helping people live healthier longer through the development and...

BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

BOSTON, Aug. 15, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation of pivotal program with RTB101 expected in the first half of 2019 BOSTON, Aug. 09, 2018 (GLOBE...

BOSTON, July 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

-- Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), the primary endpoint of...